More News

ADDF praises Alzheimer’s drug progress

Jim Cornall -
Biogen has announced topline results from its phase 2 CELIA study of diranersen, an investigational therapy designed to target...

Challenging assumptions about lymph node radiation therapy in breast cancer

Jim Cornall -
Final results from an EORTC randomised trial with more than 20 years of follow-up show that irradiation of the...

Proteins that drive fibrosis can be blocked

Jim Cornall -
The liver is often called a “silent organ,” as it can sustain significant damage without obvious symptoms. But when...

New drug candidate shows promise as brain cancer treatment

Jim Cornall -
A next-generation cancer therapy being developed at McMaster University in Canada has shown early promise as a treatment candidate...

Blood test that detects tumour DNA could help guide treatment when cancer has spread

Jim Cornall -
A blood test that detects tumour DNA circulating in the bloodstream may help select the most effective treatment options...

Hereditary epilepsy treatment

Jim Cornall -
In a world first, a research team at the University of Zurich has successfully treated mice carrying an inherited...

Myelin, a new brain regulator

Jim Cornall -
A study by Carlos Matute of the EHU-University of the Basque Country reinforces a paradigm shift in neuroscience: myelin...

Lab-designed molecule offers promising alternative for coeliac disease

Jim Cornall -
A research project led by the Institute for Research in Nutrition and Food Safety (INSA) and the Faculty of...

Base to Base biotech podcast 59: DIA helping biotech thrive, and Gorlin syndrome

Jim Cornall -
This week, we have conversations with DIA chief science and regulatory officer, Maria Vassileva, and Medicus Pharma CEO, Raza...

Positive data from AMD treatment trial

Jim Cornall -
MingMed Biotechnology Co., Ltd has announced positive results from its phase II clinical trial of QA102 in patients with...

‘Hidden switch’ in immune cells helps kill deadly fungus

Jim Cornall -
Scientists at the University of East Anglia in the UK have contributed to discovering a “control switch” inside immune...

Asthma drug in China moves forward

Jim Cornall -
Chance Pharmaceuticals has announced that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has accepted...

New coalition forms to boost US biotech

Jim Cornall -
The American Biotech Innovation Alliance (ABIA) has announced its launch, bringing together biotechnology leaders from across the US around...

Advancing Aramchol-based therapeutics

Jim Cornall -
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. have announced a collaboration to develop a novel human chronic cardiac fibrosis...

CRISPR inhibits hepatitis E virus

Jim Cornall -
Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific therapies are still lacking. A...

Biotech searches for alternative to Red 40

Jim Cornall -
Debut and Oterra have announced a multi-million-dollar collaboration to develop and scale a natural alternative to artificial red colours...

Antibody spurs nerve fibre regrowth after spinal cord injury

Jim Cornall -
An international research group has shown that the antibody NG101 promotes the regeneration of damaged spinal cord tissue. Now,...

Basel life sciences supercluster welcomes Korean biopharmas

Jim Cornall -
Basel Area Business & Innovation, the strategic growth partner helping ventures in science and tech to land, launch and...

Study shows IL-23 inhibitor demonstrates efficacy in perianal fistulizing Crohn’s disease

Jim Cornall -
Johnson & Johnson has announced results from its phase 3 FUZION study evaluating TREMFYA (guselkumab) in adults with active...

Hand-held probe maps cancerous tissue

Jim Cornall -
Breast cancer impacts more than 2m women around the world each year. Following radiotherapy or chemotherapy, breast-conserving surgery is...

Cells “back up” DNA replication to survive damage

Jim Cornall -
Every time a cell divides, it must copy its DNA with extreme precision. But this process is constantly challenged...